SCHEMBL119269

SCHEMBL119269

COC(=O)c1ccc(S(=O)(=O)NCc2ccccc2)cc1F

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.64
KMT2A Q03164 4/20 0.59
MAPT P10636 3/20 0.59
POLB P06746 4/20 0.58
ALDH1A1 P00352 4/20 0.54
PKM P14618 1/20 0.54
LMNA P02545 3/20 0.54
MAPK1 P28482 2/20 0.54
RAB9A P51151 1/20 0.54
KDM4E B2RXH2 4/20 0.52
HPGD P15428 2/20 0.52
CA12 O43570 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
ATM Q13315 1/20 0.51
CA9 Q16790 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
HTT P42858 1/20 0.51
MEN1 O00255 1/20 0.51
GRIN1 Q05586 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL119014 0.86 POLB (0.61) SMN1; SMN2KMT2AMAPTPOLBALDH1A1
SCHEMBL119882 0.85 SMN1; SMN2 (0.67) SMN1; SMN2KMT2AMAPTPOLBALDH1A1
SCHEMBL31020364 0.84 MAPT (0.47) SMN1; SMN2KMT2AMAPTPOLBALDH1A1
SCHEMBL27457377 0.81 ALDH1A1 (0.50) KMT2AMAPTALDH1A1PKMMAPK1
SCHEMBL1169744 0.81 CYP19A1 (0.54) SMN1; SMN2KMT2APOLBALDH1A1MAPK1
SCHEMBL18422643 0.80 F2 (0.47) SMN1; SMN2KMT2AMAPTPOLBALDH1A1
SCHEMBL1169813 0.79 CYP19A1 (0.60) SMN1; SMN2POLBLMNAMAPK1KDM4E
SCHEMBL119461 0.79 POLB (0.72) SMN1; SMN2MAPTPOLBALDH1A1PKM
SCHEMBL1169693 0.78 LMNA (0.54) SMN1; SMN2POLBALDH1A1LMNAMAPK1
SCHEMBL30953993 0.78 MAPT (0.45) SMN1; SMN2KMT2AMAPTALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
EP-2424517-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RaQualia Pharma Inc (JP) 2012-03-07 EP disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 SMN1; SMN2 1501/4885KMT2A 941/4885MAPT 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.